The Center for Biosimilars® recaps the top stories for the week of September 16, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 16, 2019.
Number 5: Innovator drug maker Roche says that it plans to see substantial erosion of its sales of rituximab, trastuzumab, and bevacizumab products by 2023.
Number 4: The American College of Rheumatology says that a large proportion of patients with rheumatic diseases had difficulty accessing and paying for their therapies in the past year.
Number 3: The Biosimilars Council has issued part 2 of its recent white paper on barriers to biosimilars in the United States; the newly published segment highlights post-market challenges to biosimilar adoption.
Number 2: A recent study says that step therapy in rheumatoid arthritis or psoriatic arthritis can hurt treatment outcomes.
Number 1: The United States Court of Appeals for the Third Circuit sided with Johnson & Johnson, requiring a dispute between the drug maker and Rochester Drug Cooperative to be sent to arbitration.
Finally, last week, our e-newsletter asked whether you think that Europe’s biosimilars market faces challenges to sustainability.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.